Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
editorial
. 1992 Jul;66(1):10–19. doi: 10.1038/bjc.1992.209

Towards selective pharmacological modulation of protein kinase C--opportunities for the development of novel antineoplastic agents.

A Gescher
PMCID: PMC1977896  PMID: 1637658

Full text

PDF
10

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams J. C., Gullick W. J. Differences in phorbol-ester-induced down-regulation of protein kinase C between cell lines. Biochem J. 1989 Feb 1;257(3):905–911. doi: 10.1042/bj2570905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Akinaga S., Gomi K., Morimoto M., Tamaoki T., Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res. 1991 Sep 15;51(18):4888–4892. [PubMed] [Google Scholar]
  3. Akita Y., Ohno S., Konno Y., Yano A., Suzuki K. Expression and properties of two distinct classes of the phorbol ester receptor family, four conventional protein kinase C types, and a novel protein kinase C. J Biol Chem. 1990 Jan 5;265(1):354–362. [PubMed] [Google Scholar]
  4. Aquino A., Warren B. S., Omichinski J., Hartman K. D., Glazer R. I. Protein kinase C-gamma is present in adriamycin resistant HL-60 leukemia cells. Biochem Biophys Res Commun. 1990 Jan 30;166(2):723–728. doi: 10.1016/0006-291x(90)90869-o. [DOI] [PubMed] [Google Scholar]
  5. Ase K., Berry N., Kikkawa U., Kishimoto A., Nishizuka Y. Differential down-regulation of protein kinase C subspecies in KM3 cells. FEBS Lett. 1988 Aug 29;236(2):396–400. doi: 10.1016/0014-5793(88)80064-4. [DOI] [PubMed] [Google Scholar]
  6. Barr L. F., Mabry M., Nelkin B. D., Tyler G., May W. S., Baylin S. B. c-myc gene-induced alterations in protein kinase C expression: a possible mechanism facilitating myc-ras gene complementation. Cancer Res. 1991 Oct 15;51(20):5514–5519. [PubMed] [Google Scholar]
  7. Basu A., Kozikowski A. P., Sato K., Lazo J. S. Cellular sensitization to cis-diamminedichloroplatinum(II) by novel analogues of the protein kinase C activator lyngbyatoxin A. Cancer Res. 1991 May 15;51(10):2511–2514. [PubMed] [Google Scholar]
  8. Basu A., Teicher B. A., Lazo J. S. Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). J Biol Chem. 1990 May 25;265(15):8451–8457. [PubMed] [Google Scholar]
  9. Becker D., Beebe S. J., Herlyn M. Differential expression of protein kinase C and cAMP-dependent protein kinase in normal human melanocytes and malignant melanomas. Oncogene. 1990 Aug;5(8):1133–1139. [PubMed] [Google Scholar]
  10. Beckwith M., Longo D. L., O'Connell C. D., Moratz C. M., Urba W. J. Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. J Natl Cancer Inst. 1990 Mar 21;82(6):501–509. doi: 10.1093/jnci/82.6.501. [DOI] [PubMed] [Google Scholar]
  11. Beh I., Schmidt R., Hecker E. Two isozymes of PKC found in HL-60 cells show a difference in activation by the phorbol ester TPA. FEBS Lett. 1989 Jun 5;249(2):264–266. doi: 10.1016/0014-5793(89)80637-4. [DOI] [PubMed] [Google Scholar]
  12. Berkow R. L., Kraft A. S. Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. Biochem Biophys Res Commun. 1985 Sep 30;131(3):1109–1116. doi: 10.1016/0006-291x(85)90205-0. [DOI] [PubMed] [Google Scholar]
  13. Blumberg P. M. Complexities of the protein kinase C pathway. Mol Carcinog. 1991;4(5):339–344. doi: 10.1002/mc.2940040502. [DOI] [PubMed] [Google Scholar]
  14. Borner C., Filipuzzi I., Weinstein I. B., Imber R. Failure of wild-type or a mutant form of protein kinase C-alpha to transform fibroblasts. Nature. 1991 Sep 5;353(6339):78–80. doi: 10.1038/353078a0. [DOI] [PubMed] [Google Scholar]
  15. Borner C., Guadagno S. N., Hsieh L. L., Hsiao W. L., Weinstein I. B. Transformation by a ras oncogene causes increased expression of protein kinase C-alpha and decreased expression of protein kinase C-epsilon. Cell Growth Differ. 1990 Dec;1(12):653–660. [PubMed] [Google Scholar]
  16. Bottega R., Epand R. M., Ball E. H. Inhibition of protein kinase C by sphingosine correlates with the presence of positive charge. Biochem Biophys Res Commun. 1989 Oct 16;164(1):102–107. doi: 10.1016/0006-291x(89)91688-4. [DOI] [PubMed] [Google Scholar]
  17. Bradshaw T. D., Gescher A., Pettit G. R. The effect of fetal calf serum on growth arrest caused by activators of protein kinase C. Int J Cancer. 1991 Apr 1;47(6):929–932. doi: 10.1002/ijc.2910470624. [DOI] [PubMed] [Google Scholar]
  18. Brooks G., Birch M., Hart I. R. Effects of biologically active tumour-promoting and non-promoting phorbol esters on in vitro growth of melanocytic cells. Pigment Cell Res. 1990 Mar-Apr;3(2):98–100. doi: 10.1111/j.1600-0749.1990.tb00328.x. [DOI] [PubMed] [Google Scholar]
  19. Brooks G., Evans A. T., Aitken A., Evans F. J. Tumour-promoting and hyperplastic effects of phorbol and daphnane esters in CD-1 mouse skin and a synergistic effect of calcium ionophore with the non-promoting activator of protein kinase C, sapintoxin A. Carcinogenesis. 1989 Feb;10(2):283–288. doi: 10.1093/carcin/10.2.283. [DOI] [PubMed] [Google Scholar]
  20. Brooks G., Wilson R. E., Dooley T. P., Goss M. W., Hart I. R. Protein kinase C down-regulation, and not transient activation, correlates with melanocyte growth. Cancer Res. 1991 Jun 15;51(12):3281–3288. [PubMed] [Google Scholar]
  21. Choi P. M., Tchou-Wong K. M., Weinstein I. B. Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression. Mol Cell Biol. 1990 Sep;10(9):4650–4657. doi: 10.1128/mcb.10.9.4650. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Choi P. M., Weinstein I. B. The modulation of growth by HMBA in PKC overproducing HT29 colon cancer cells. Biochem Biophys Res Commun. 1991 Dec 16;181(2):809–817. doi: 10.1016/0006-291x(91)91262-b. [DOI] [PubMed] [Google Scholar]
  23. Dale I. L., Bradshaw T. D., Gescher A., Pettit G. R. Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells. Cancer Res. 1989 Jun 15;49(12):3242–3245. [PubMed] [Google Scholar]
  24. Dale I. L., Gescher A. Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells. Int J Cancer. 1989 Jan 15;43(1):158–163. doi: 10.1002/ijc.2910430129. [DOI] [PubMed] [Google Scholar]
  25. Davis P. D., Hill C. H., Keech E., Lawton G., Nixon J. S., Sedgwick A. D., Wadsworth J., Westmacott D., Wilkinson S. E. Potent selective inhibitors of protein kinase C. FEBS Lett. 1989 Dec 18;259(1):61–63. doi: 10.1016/0014-5793(89)81494-2. [DOI] [PubMed] [Google Scholar]
  26. Dell'Aquila M. L., Nguyen H. T., Herald C. L., Pettit G. R., Blumberg P. M. Inhibition by bryostatin 1 of the phorbol ester-induced blockage of differentiation in hexamethylene bisacetamide-treated Friend erythroleukemia cells. Cancer Res. 1987 Nov 15;47(22):6006–6009. [PubMed] [Google Scholar]
  27. Dieter P., Fitzke E. RO 31-8220 and RO 31-7549 show improved selectivity for protein kinase C over staurosporine in macrophages. Biochem Biophys Res Commun. 1991 Nov 27;181(1):396–401. doi: 10.1016/s0006-291x(05)81432-9. [DOI] [PubMed] [Google Scholar]
  28. Dlugosz A. A., Yuspa S. H. Staurosporine induces protein kinase C agonist effects and maturation of normal and neoplastic mouse keratinocytes in vitro. Cancer Res. 1991 Sep 1;51(17):4677–4684. [PubMed] [Google Scholar]
  29. Dong Z. Y., Ward N. E., Fan D., Gupta K. P., O'Brian C. A. In vitro model for intrinsic drug resistance: effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells. Mol Pharmacol. 1991 Apr;39(4):563–569. [PubMed] [Google Scholar]
  30. Eichholtz T., Alblas J., van Overveld M., Moolenaar W., Ploegh H. A pseudosubstrate peptide inhibits protein kinase C-mediated phosphorylation in permeabilized Rat-1 cells. FEBS Lett. 1990 Feb 12;261(1):147–150. doi: 10.1016/0014-5793(90)80657-5. [DOI] [PubMed] [Google Scholar]
  31. Endo K., Igarashi Y., Nisar M., Zhou Q. H., Hakomori S. Cell membrane signaling as target in cancer therapy: inhibitory effect of N,N-dimethyl and N,N,N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice. Cancer Res. 1991 Mar 15;51(6):1613–1618. [PubMed] [Google Scholar]
  32. Fields A. P., Pettit G. R., May W. S. Phosphorylation of lamin B at the nuclear membrane by activated protein kinase C. J Biol Chem. 1988 Jun 15;263(17):8253–8260. [PubMed] [Google Scholar]
  33. Ford J. M., Hait W. N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev. 1990 Sep;42(3):155–199. [PubMed] [Google Scholar]
  34. Geilen C. C., Haase R., Buchner K., Wieder T., Hucho F., Reutter W. The phospholipid analogue, hexadecylphosphocholine, inhibits protein kinase C in vitro and antagonises phorbol ester-stimulated cell proliferation. Eur J Cancer. 1991;27(12):1650–1653. doi: 10.1016/0277-5379(91)90438-j. [DOI] [PubMed] [Google Scholar]
  35. Gescher A. Antiproliferative properties of phorbol ester tumour promoters. Biochem Pharmacol. 1985 Aug 1;34(15):2587–2592. doi: 10.1016/0006-2952(85)90552-0. [DOI] [PubMed] [Google Scholar]
  36. Gschwendt M., Leibersperger H., Marks F. Differentiative action of K252a on protein kinase C and a calcium-unresponsive, phorbol ester/phospholipid-activated protein kinase. Biochem Biophys Res Commun. 1989 Nov 15;164(3):974–982. doi: 10.1016/0006-291x(89)91765-8. [DOI] [PubMed] [Google Scholar]
  37. Hannun Y. A., Bell R. M. Aminoacridines, potent inhibitors of protein kinase C. J Biol Chem. 1988 Apr 15;263(11):5124–5131. [PubMed] [Google Scholar]
  38. Hannun Y. A., Bell R. M. Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science. 1989 Jan 27;243(4890):500–507. doi: 10.1126/science.2643164. [DOI] [PubMed] [Google Scholar]
  39. Hannun Y. A., Bell R. M. Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses. Science. 1987 Feb 6;235(4789):670–674. doi: 10.1126/science.3101176. [DOI] [PubMed] [Google Scholar]
  40. Hannun Y. A., Foglesong R. J., Bell R. M. The adriamycin-iron(III) complex is a potent inhibitor of protein kinase C. J Biol Chem. 1989 Jun 15;264(17):9960–9966. [PubMed] [Google Scholar]
  41. Hass R., Pfannkuche H. J., Kharbanda S., Gunji H., Meyer G., Hartmann A., Hidaka H., Resch K., Kufe D., Goppelt-Strübe M. Protein kinase C activation and protooncogene expression in differentiation/retrodifferentiation of human U-937 leukemia cells. Cell Growth Differ. 1991 Nov;2(11):541–548. [PubMed] [Google Scholar]
  42. Hecker E. Cell membrane associated protein kinase C as receptor of diterpene ester co-carcinogens of the tumor promoter type and the phenotypic expression of tumors. Arzneimittelforschung. 1985;35(12A):1890–1903. [PubMed] [Google Scholar]
  43. Heesbeen E. C., Verdonck L. F., Hermans S. W., van Heugten H. G., Staal G. E., Rijksen G. Alkyllysophospholipid ET-18-OCH3 acts as an activator of protein kinase C in HL-60 cells. FEBS Lett. 1991 Sep 23;290(1-2):231–234. doi: 10.1016/0014-5793(91)81267-c. [DOI] [PubMed] [Google Scholar]
  44. Hennings H., Blumberg P. M., Pettit G. R., Herald C. L., Shores R., Yuspa S. H. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis. 1987 Sep;8(9):1343–1346. doi: 10.1093/carcin/8.9.1343. [DOI] [PubMed] [Google Scholar]
  45. Herbert J. M., Augereau J. M., Gleye J., Maffrand J. P. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun. 1990 Nov 15;172(3):993–999. doi: 10.1016/0006-291x(90)91544-3. [DOI] [PubMed] [Google Scholar]
  46. Hess A. D., Silanskis M. K., Esa A. H., Pettit G. R., May W. S. Activation of human T lymphocytes by bryostatin. J Immunol. 1988 Nov 15;141(10):3263–3269. [PubMed] [Google Scholar]
  47. Hidaka H., Inagaki M., Kawamoto S., Sasaki Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry. 1984 Oct 9;23(21):5036–5041. doi: 10.1021/bi00316a032. [DOI] [PubMed] [Google Scholar]
  48. Hirai M., Gamou S., Kobayashi M., Shimizu N. Lung cancer cells often express high levels of protein kinase C activity. Jpn J Cancer Res. 1989 Mar;80(3):204–208. doi: 10.1111/j.1349-7006.1989.tb02292.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Hocevar B. A., Fields A. P. Selective translocation of beta II-protein kinase C to the nucleus of human promyelocytic (HL60) leukemia cells. J Biol Chem. 1991 Jan 5;266(1):28–33. [PubMed] [Google Scholar]
  50. Hooper W. C., Abraham R. T., Ashendel C. L., Woloschak G. E. Differential responsiveness to phorbol esters correlates with differential expression of protein kinase C in KG-1 and KG-1a human myeloid leukemia cells. Biochim Biophys Acta. 1989 Sep 4;1013(1):47–54. doi: 10.1016/0167-4889(89)90126-2. [DOI] [PubMed] [Google Scholar]
  51. Hornung R. L., Pearson J. W., Beckwith M., Longo D. L. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res. 1992 Jan 1;52(1):101–107. [PubMed] [Google Scholar]
  52. House C., Kemp B. E. Protein kinase C contains a pseudosubstrate prototope in its regulatory domain. Science. 1987 Dec 18;238(4834):1726–1728. doi: 10.1126/science.3686012. [DOI] [PubMed] [Google Scholar]
  53. House C., Wettenhall R. E., Kemp B. E. The influence of basic residues on the substrate specificity of protein kinase C. J Biol Chem. 1987 Jan 15;262(2):772–777. [PubMed] [Google Scholar]
  54. Housey G. M., Johnson M. D., Hsiao W. L., O'Brian C. A., Murphy J. P., Kirschmeier P., Weinstein I. B. Overproduction of protein kinase C causes disordered growth control in rat fibroblasts. Cell. 1988 Feb 12;52(3):343–354. doi: 10.1016/s0092-8674(88)80027-8. [DOI] [PubMed] [Google Scholar]
  55. Huang F. L., Yoshida Y., Cunha-Melo J. R., Beaven M. A., Huang K. P. Differential down-regulation of protein kinase C isozymes. J Biol Chem. 1989 Mar 5;264(7):4238–4243. [PubMed] [Google Scholar]
  56. Huang K. P., Huang F. L. Differential sensitivity of protein kinase C isozymes to phospholipid-induced inactivation. J Biol Chem. 1990 Jan 15;265(2):738–744. [PubMed] [Google Scholar]
  57. Huwiler A., Fabbro D., Pfeilschifter J. Differential recovery of protein kinase C-alpha and -epsilon isozymes after long-term phorbol ester treatment in rat renal mesangial cells. Biochem Biophys Res Commun. 1991 Nov 14;180(3):1422–1428. doi: 10.1016/s0006-291x(05)81355-5. [DOI] [PubMed] [Google Scholar]
  58. Isakov N., McMahon P., Altman A. Selective post-transcriptional down-regulation of protein kinase C isoenzymes in leukemic T cells chronically treated with phorbol ester. J Biol Chem. 1990 Feb 5;265(4):2091–2097. [PubMed] [Google Scholar]
  59. Isonishi S., Andrews P. A., Howell S. B. Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem. 1990 Mar 5;265(7):3623–3627. [PubMed] [Google Scholar]
  60. Kase H., Iwahashi K., Nakanishi S., Matsuda Y., Yamada K., Takahashi M., Murakata C., Sato A., Kaneko M. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem Biophys Res Commun. 1987 Jan 30;142(2):436–440. doi: 10.1016/0006-291x(87)90293-2. [DOI] [PubMed] [Google Scholar]
  61. Kennedy M. J., Prestigiacomo L. J., Tyler G., May W. S., Davidson N. E. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res. 1992 Mar 1;52(5):1278–1283. [PubMed] [Google Scholar]
  62. Kikkawa U., Kishimoto A., Nishizuka Y. The protein kinase C family: heterogeneity and its implications. Annu Rev Biochem. 1989;58:31–44. doi: 10.1146/annurev.bi.58.070189.000335. [DOI] [PubMed] [Google Scholar]
  63. Kiley S., Schaap D., Parker P., Hsieh L. L., Jaken S. Protein kinase C heterogeneity in GH4C1 rat pituitary cells. Characterization of a Ca2(+)-independent phorbol ester receptor. J Biol Chem. 1990 Sep 15;265(26):15704–15712. [PubMed] [Google Scholar]
  64. Kobayashi E., Nakano H., Morimoto M., Tamaoki T. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun. 1989 Mar 15;159(2):548–553. doi: 10.1016/0006-291x(89)90028-4. [DOI] [PubMed] [Google Scholar]
  65. Komada F., Nishikawa M., Uemura Y., Morita K., Hidaka H., Shirakawa S. Expression of three major protein kinase C isozymes in various types of human leukemic cells. Cancer Res. 1991 Aug 15;51(16):4271–4278. [PubMed] [Google Scholar]
  66. Kopp R., Noelke B., Sauter G., Schildberg F. W., Paumgartner G., Pfeiffer A. Altered protein kinase C activity in biopsies of human colonic adenomas and carcinomas. Cancer Res. 1991 Jan 1;51(1):205–210. [PubMed] [Google Scholar]
  67. Kraft A. S., Anderson W. B. Phorbol esters increase the amount of Ca2+, phospholipid-dependent protein kinase associated with plasma membrane. Nature. 1983 Feb 17;301(5901):621–623. doi: 10.1038/301621a0. [DOI] [PubMed] [Google Scholar]
  68. Kraft A. S., Reeves J. A., Ashendel C. L. Differing modulation of protein kinase C by bryostatin 1 and phorbol esters in JB6 mouse epidermal cells. J Biol Chem. 1988 Jun 15;263(17):8437–8442. [PubMed] [Google Scholar]
  69. Kraft A. S., Smith J. B., Berkow R. L. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci U S A. 1986 Mar;83(5):1334–1338. doi: 10.1073/pnas.83.5.1334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Krauss R. S., Housey G. M., Johnson M. D., Weinstein I. B. Disturbances in growth control and gene expression in a C3H/10T1/2 cell line that stably overproduces protein kinase C. Oncogene. 1989 Aug;4(8):991–998. [PubMed] [Google Scholar]
  71. Laughton C. A., Bradshaw T. D., Gescher A. Sterically hindered analogues of diacylglycerols. Synthesis, binding to the phorbol ester receptor and metabolism in A549 human lung carcinoma cells. Int J Cancer. 1989 Aug 15;44(2):320–324. doi: 10.1002/ijc.2910440222. [DOI] [PubMed] [Google Scholar]
  72. Laughton C. A., Dale I. L., Gescher A. Studies on bioactive compounds. 13. Synthesis and lack of growth-inhibitory properties of cyclohexane-1,2,4-triol 1,2-diesters, which resemble ring C of the phorbol ester molecule. J Med Chem. 1989 Feb;32(2):428–433. doi: 10.1021/jm00122a023. [DOI] [PubMed] [Google Scholar]
  73. Lilly M., Brown C., Pettit G., Kraft A. Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia. Leukemia. 1991 Apr;5(4):283–287. [PubMed] [Google Scholar]
  74. Lindner D., Gschwendt M., Marks F. Down-regulation of protein kinase C in Swiss 3T3 fibroblasts is independent of its phosphorylating activity. Biochem Biophys Res Commun. 1991 May 15;176(3):1227–1231. doi: 10.1016/0006-291x(91)90416-5. [DOI] [PubMed] [Google Scholar]
  75. Loomis C. R., Bell R. M. Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C. J Biol Chem. 1988 Feb 5;263(4):1682–1692. [PubMed] [Google Scholar]
  76. Mackanos E. A., Pettit G. R., Ramsdell J. S. Bryostatins selectively regulate protein kinase C-mediated effects on GH4 cell proliferation. J Biol Chem. 1991 Jun 15;266(17):11205–11212. [PubMed] [Google Scholar]
  77. Mahoney C. W., Azzi A., Huang K. P. Effects of suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C. Differential activation and inhibition of protein kinase C isozymes. J Biol Chem. 1990 Apr 5;265(10):5424–5428. [PubMed] [Google Scholar]
  78. Marais R. M., Parker P. J. Purification and characterisation of bovine brain protein kinase C isotypes alpha, beta and gamma. Eur J Biochem. 1989 Jun 1;182(1):129–137. doi: 10.1111/j.1432-1033.1989.tb14809.x. [DOI] [PubMed] [Google Scholar]
  79. Marx M. H., Piantadosi C., Noseda A., Daniel L. W., Modest E. J. Synthesis and evaluation of neoplastic cell growth inhibition of 1-N-alkylamide analogues of glycero-3-phosphocholine. J Med Chem. 1988 Apr;31(4):858–863. doi: 10.1021/jm00399a029. [DOI] [PubMed] [Google Scholar]
  80. May W. S., Sharkis S. J., Esa A. H., Gebbia V., Kraft A. S., Pettit G. R., Sensenbrenner L. L. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci U S A. 1987 Dec;84(23):8483–8487. doi: 10.1073/pnas.84.23.8483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. McBain J. A., Pettit G. R., Mueller G. C. Bryostatin 1 antagonizes the terminal differentiating action of 12-O-tetradecanoylphorbol-13-acetate in a human colon cancer cell. Carcinogenesis. 1988 Jan;9(1):123–129. doi: 10.1093/carcin/9.1.123. [DOI] [PubMed] [Google Scholar]
  82. McSwine-Kennick R. L., McKeegan E. M., Johnson M. D., Morin M. J. Phorbol diester-induced alterations in the expression of protein kinase C isozymes and their mRNAs. Analysis in wild-type and phorbol diester-resistant HL-60 cell clones. J Biol Chem. 1991 Aug 15;266(23):15135–15143. [PubMed] [Google Scholar]
  83. Megidish T., Mazurek N. A mutant protein kinase C that can transform fibroblasts. Nature. 1989 Dec 14;342(6251):807–811. doi: 10.1038/342807a0. [DOI] [PubMed] [Google Scholar]
  84. Merrill A. H., Jr, Nimkar S., Menaldino D., Hannun Y. A., Loomis C., Bell R. M., Tyagi S. R., Lambeth J. D., Stevens V. L., Hunter R. Structural requirements for long-chain (sphingoid) base inhibition of protein kinase C in vitro and for the cellular effects of these compounds. Biochemistry. 1989 Apr 18;28(8):3138–3145. doi: 10.1021/bi00434a004. [DOI] [PubMed] [Google Scholar]
  85. Meyer T., Regenass U., Fabbro D., Alteri E., Rösel J., Müller M., Caravatti G., Matter A. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer. 1989 May 15;43(5):851–856. doi: 10.1002/ijc.2910430519. [DOI] [PubMed] [Google Scholar]
  86. Mochly-Rosen D., Khaner H., Lopez J., Smith B. L. Intracellular receptors for activated protein kinase C. Identification of a binding site for the enzyme. J Biol Chem. 1991 Aug 15;266(23):14866–14868. [PubMed] [Google Scholar]
  87. Molleyres L. P., Rando R. R. Structural studies on the diglyceride-mediated activation of protein kinase C. J Biol Chem. 1988 Oct 15;263(29):14832–14838. [PubMed] [Google Scholar]
  88. Mori T., Takai Y., Minakuchi R., Yu B., Nishizuka Y. Inhibitory action of chlorpromazine, dibucaine, and other phospholipid-interacting drugs on calcium-activated, phospholipid-dependent protein kinase. J Biol Chem. 1980 Sep 25;255(18):8378–8380. [PubMed] [Google Scholar]
  89. Morin M. J., Kreutter D., Rasmussen H., Sartorelli A. C. Disparate effects of activators of protein kinase C on HL-60 promyelocytic leukemia cell differentiation. J Biol Chem. 1987 Aug 25;262(24):11758–11763. [PubMed] [Google Scholar]
  90. Nishikawa M., Komada F., Uemura Y., Hidaka H., Shirakawa S. Decreased expression of type II protein kinase C in HL-60 variant cells resistant to induction of cell differentiation by phorbol diester. Cancer Res. 1990 Feb 1;50(3):621–626. [PubMed] [Google Scholar]
  91. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature. 1988 Aug 25;334(6184):661–665. doi: 10.1038/334661a0. [DOI] [PubMed] [Google Scholar]
  92. O'Brian C. A., Liskamp R. M., Solomon D. H., Weinstein I. B. Inhibition of protein kinase C by tamoxifen. Cancer Res. 1985 Jun;45(6):2462–2465. [PubMed] [Google Scholar]
  93. O'Brian C., Vogel V. G., Singletary S. E., Ward N. E. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res. 1989 Jun 15;49(12):3215–3217. [PubMed] [Google Scholar]
  94. Obeid L. M., Okazaki T., Karolak L. A., Hannun Y. A. Transcriptional regulation of protein kinase C by 1,25-dihydroxyvitamin D3 in HL-60 cells. J Biol Chem. 1990 Feb 5;265(4):2370–2374. [PubMed] [Google Scholar]
  95. Okoshi H., Hakomori S., Nisar M., Zhou Q. H., Kimura S., Tashiro K., Igarashi Y. Cell membrane signaling as target in cancer therapy. II: Inhibitory effect of N,N,N-trimethylsphingosine on metastatic potential of murine B16 melanoma cell line through blocking of tumor cell-dependent platelet aggregation. Cancer Res. 1991 Nov 15;51(22):6019–6024. [PubMed] [Google Scholar]
  96. Ono Y., Fujii T., Ogita K., Kikkawa U., Igarashi K., Nishizuka Y. Protein kinase C zeta subspecies from rat brain: its structure, expression, and properties. Proc Natl Acad Sci U S A. 1989 May;86(9):3099–3103. doi: 10.1073/pnas.86.9.3099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Parker P. J., Kour G., Marais R. M., Mitchell F., Pears C., Schaap D., Stabel S., Webster C. Protein kinase C--a family affair. Mol Cell Endocrinol. 1989 Aug;65(1-2):1–11. doi: 10.1016/0303-7207(89)90159-7. [DOI] [PubMed] [Google Scholar]
  98. Pasti G., Rivedal E., Yuspa S. H., Herald C. L., Pettit G. R., Blumberg P. M. Contrasting duration of inhibition of cell-cell communication in primary mouse epidermal cells by phorbol 12,13-dibutyrate and by bryostatin 1. Cancer Res. 1988 Jan 15;48(2):447–451. [PubMed] [Google Scholar]
  99. Pears C., Parker P. J. Down-regulation of a kinase defective PKC-alpha. FEBS Lett. 1991 Jun 17;284(1):120–122. doi: 10.1016/0014-5793(91)80776-y. [DOI] [PubMed] [Google Scholar]
  100. Pearson J. D., DeWald D. B., Mathews W. R., Mozier N. M., Zürcher-Neely H. A., Heinrikson R. L., Morris M. A., McCubbin W. D., McDonald J. R., Fraser E. D. Amino acid sequence and characterization of a protein inhibitor of protein kinase C. J Biol Chem. 1990 Mar 15;265(8):4583–4591. [PubMed] [Google Scholar]
  101. Pelosin J. M., Keramidas M., Souvignet C., Chambaz E. M. Differential inhibition of protein kinase C subtypes. Biochem Biophys Res Commun. 1990 Jun 29;169(3):1040–1048. doi: 10.1016/0006-291x(90)91999-9. [DOI] [PubMed] [Google Scholar]
  102. Persons D. A., Wilkison W. O., Bell R. M., Finn O. J. Altered growth regulation and enhanced tumorigenicity of NIH 3T3 fibroblasts transfected with protein kinase C-I cDNA. Cell. 1988 Feb 12;52(3):447–458. doi: 10.1016/s0092-8674(88)80037-0. [DOI] [PubMed] [Google Scholar]
  103. Pettit G. R., Day J. F., Hartwell J. L., Wood H. B. Antineoplastic components of marine animals. Nature. 1970 Aug 29;227(5261):962–963. doi: 10.1038/227962a0. [DOI] [PubMed] [Google Scholar]
  104. Pontremoli S., Melloni E., Sparatore B., Michetti M., Salamino F., Horecker B. L. Isozymes of protein kinase C in human neutrophils and their modification by two endogenous proteinases. J Biol Chem. 1990 Jan 15;265(2):706–712. [PubMed] [Google Scholar]
  105. Posada J. A., McKeegan E. M., Worthington K. F., Morin M. J., Jaken S., Tritton T. R. Human multidrug resistant KB cells overexpress protein kinase C: involvement in drug resistance. Cancer Commun. 1989;1(5):285–292. doi: 10.3727/095535489820874922. [DOI] [PubMed] [Google Scholar]
  106. Powis G. Signalling targets for anticancer drug development. Trends Pharmacol Sci. 1991 May;12(5):188–194. doi: 10.1016/0165-6147(91)90545-4. [DOI] [PubMed] [Google Scholar]
  107. Rando R. R., Kishi Y. Structural basis of protein kinase C activation by diacylglycerols and tumor promoters. Biochemistry. 1992 Mar 3;31(8):2211–2218. doi: 10.1021/bi00123a001. [DOI] [PubMed] [Google Scholar]
  108. Reddy A. L., Fialkow P. J. Evidence that weak promotion of carcinogen-initiated cells prevents their progression to malignancy. Carcinogenesis. 1990 Dec;11(12):2123–2126. doi: 10.1093/carcin/11.12.2123. [DOI] [PubMed] [Google Scholar]
  109. Rodriguez-Pena A., Rozengurt E. Disappearance of Ca2+-sensitive, phospholipid-dependent protein kinase activity in phorbol ester-treated 3T3 cells. Biochem Biophys Res Commun. 1984 May 16;120(3):1053–1059. doi: 10.1016/s0006-291x(84)80213-2. [DOI] [PubMed] [Google Scholar]
  110. Rotenberg S. A., Smiley S., Ueffing M., Krauss R. S., Chen L. B., Weinstein I. B. Inhibition of rodent protein kinase C by the anticarcinoma agent dequalinium. Cancer Res. 1990 Feb 1;50(3):677–685. [PubMed] [Google Scholar]
  111. Ryves W. J., Evans A. T., Olivier A. R., Parker P. J., Evans F. J. Activation of the PKC-isotypes alpha, beta 1, gamma, delta and epsilon by phorbol esters of different biological activities. FEBS Lett. 1991 Aug 19;288(1-2):5–9. doi: 10.1016/0014-5793(91)80989-g. [DOI] [PubMed] [Google Scholar]
  112. Sakanoue Y., Hatada T., Kusunoki M., Yanagi H., Yamamura T., Utsunomiya J. Protein kinase C activity as marker for colorectal cancer. Int J Cancer. 1991 Jul 30;48(6):803–806. doi: 10.1002/ijc.2910480602. [DOI] [PubMed] [Google Scholar]
  113. Sako T., Yuspa S. H., Herald C. L., Pettit G. R., Blumberg P. M. Partial parallelism and partial blockade by bryostatin 1 of effects of phorbol ester tumor promoters on primary mouse epidermal cells. Cancer Res. 1987 Oct 15;47(20):5445–5450. [PubMed] [Google Scholar]
  114. Schaap D., Hsuan J., Totty N., Parker P. J. Proteolytic activation of protein kinase C-epsilon. Eur J Biochem. 1990 Jul 31;191(2):431–435. doi: 10.1111/j.1432-1033.1990.tb19139.x. [DOI] [PubMed] [Google Scholar]
  115. Schaap D., Parker P. J., Bristol A., Kriz R., Knopf J. Unique substrate specificity and regulatory properties of PKC-epsilon: a rationale for diversity. FEBS Lett. 1989 Jan 30;243(2):351–357. doi: 10.1016/0014-5793(89)80160-7. [DOI] [PubMed] [Google Scholar]
  116. Schaap D., Parker P. J. Expression, purification, and characterization of protein kinase C-epsilon. J Biol Chem. 1990 May 5;265(13):7301–7307. [PubMed] [Google Scholar]
  117. Schuchter L. M., Esa A. H., May S., Laulis M. K., Pettit G. R., Hess A. D. Successful treatment of murine melanoma with bryostatin 1. Cancer Res. 1991 Jan 15;51(2):682–687. [PubMed] [Google Scholar]
  118. Schwartz G. K., Redwood S. M., Ohnuma T., Holland J. F., Droller M. J., Liu B. C. Inhibition of invasion of invasive human bladder carcinoma cells by protein kinase C inhibitor staurosporine. J Natl Cancer Inst. 1990 Nov 21;82(22):1753–1756. doi: 10.1093/jnci/82.22.1753. [DOI] [PubMed] [Google Scholar]
  119. Sekiguchi K., Tsukuda M., Ogita K., Kikkawa U., Nishizuka Y. Three distinct forms of rat brain protein kinase C: differential response to unsaturated fatty acids. Biochem Biophys Res Commun. 1987 Jun 15;145(2):797–802. doi: 10.1016/0006-291x(87)91035-7. [DOI] [PubMed] [Google Scholar]
  120. Shimizu N., Ohta M., Fujiwara C., Sagara J., Mochizuki N., Oda T., Utiyama H. Expression of a novel immediate early gene during 12-O-tetradecanoylphorbol-13-acetate-induced macrophagic differentiation of HL-60 cells. J Biol Chem. 1991 Jul 5;266(19):12157–12161. [PubMed] [Google Scholar]
  121. Shimizu Y., Shimizu N. Cell genetic evidence of correlation of intracellular translocation of protein kinase C (PKC) and PKC-mediated phosphorylation of 80-kDa protein with mitogenic action of tumor promoters. Somat Cell Mol Genet. 1989 Jul;15(4):321–329. doi: 10.1007/BF01534971. [DOI] [PubMed] [Google Scholar]
  122. Smith J. B., Smith L., Pettit G. R. Bryostatins: potent, new mitogens that mimic phorbol ester tumor promoters. Biochem Biophys Res Commun. 1985 Nov 15;132(3):939–945. doi: 10.1016/0006-291x(85)91898-4. [DOI] [PubMed] [Google Scholar]
  123. Stabel S., Parker P. J. Protein kinase C. Pharmacol Ther. 1991;51(1):71–95. doi: 10.1016/0163-7258(91)90042-k. [DOI] [PubMed] [Google Scholar]
  124. Stevens V. L., Nimkar S., Jamison W. C., Liotta D. C., Merrill A. H., Jr Characteristics of the growth inhibition and cytotoxicity of long-chain (sphingoid) bases for Chinese hamster ovary cells: evidence for an involvement of protein kinase C. Biochim Biophys Acta. 1990 Jan 23;1051(1):37–45. doi: 10.1016/0167-4889(90)90171-9. [DOI] [PubMed] [Google Scholar]
  125. Strulovici B., Daniel-Issakani S., Baxter G., Knopf J., Sultzman L., Cherwinski H., Nestor J., Jr, Webb D. R., Ransom J. Distinct mechanisms of regulation of protein kinase C epsilon by hormones and phorbol diesters. J Biol Chem. 1991 Jan 5;266(1):168–173. [PubMed] [Google Scholar]
  126. Sullivan J. P., Connor J. R., Shearer B. G., Burch R. M. 2,6-Diamino-N-([1-oxotridecyl)-2-piperidinyl]methyl)hexanamide (NPC 15437): a selective inhibitor of protein kinase C. Agents Actions. 1991 Sep;34(1-2):142–144. doi: 10.1007/BF01993261. [DOI] [PubMed] [Google Scholar]
  127. Tamaoki T., Nakano H. Potent and specific inhibitors of protein kinase C of microbial origin. Biotechnology (N Y) 1990 Aug;8(8):732–735. doi: 10.1038/nbt0890-732. [DOI] [PubMed] [Google Scholar]
  128. Tamaoki T., Nomoto H., Takahashi I., Kato Y., Morimoto M., Tomita F. Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase. Biochem Biophys Res Commun. 1986 Mar 13;135(2):397–402. doi: 10.1016/0006-291x(86)90008-2. [DOI] [PubMed] [Google Scholar]
  129. Trilivas I., McDonough P. M., Brown J. H. Dissociation of protein kinase C redistribution from the phosphorylation of its substrates. J Biol Chem. 1991 May 5;266(13):8431–8438. [PubMed] [Google Scholar]
  130. Tritton T. R., Hickman J. A. How to kill cancer cells: membranes and cell signaling as targets in cancer chemotherapy. Cancer Cells. 1990 Apr;2(4):95–105. [PubMed] [Google Scholar]
  131. Uberall F., Maly K., Egle A., Doppler W., Hofmann J., Grunicke H. H. Inhibition of cell proliferation, protein kinase C, and phorbol ester-induced fos expression by the dihydropyridine derivative B859-35. Cancer Res. 1991 Nov 1;51(21):5821–5825. [PubMed] [Google Scholar]
  132. Uberall F., Oberhuber H., Maly K., Zaknun J., Demuth L., Grunicke H. H. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res. 1991 Feb 1;51(3):807–812. [PubMed] [Google Scholar]
  133. Valette A., Gas N., Jozan S., Roubinet F., Dupont M. A., Bayard F. Influence of 12-O-tetradecanoylphorbol-13-acetate on proliferation and maturation of human breast carcinoma cells (MCF-7): relationship to cell cycle events. Cancer Res. 1987 Mar 15;47(6):1615–1620. [PubMed] [Google Scholar]
  134. Vandenbark G. R., Niedel J. E. Phorbol diesters and cellular differentiation. J Natl Cancer Inst. 1984 Nov;73(5):1013–1019. [PubMed] [Google Scholar]
  135. Warren B. S., Kamano Y., Pettit G. R., Blumberg P. M. Mimicry of bryostatin 1 induced phosphorylation patterns in HL-60 cells by high-phorbol ester concentrations. Cancer Res. 1988 Nov 1;48(21):5984–5988. [PubMed] [Google Scholar]
  136. Weinstein I. B. The origins of human cancer: molecular mechanisms of carcinogenesis and their implications for cancer prevention and treatment--twenty-seventh G.H.A. Clowes memorial award lecture. Cancer Res. 1988 Aug 1;48(15):4135–4143. [PubMed] [Google Scholar]
  137. Wender P. A., Cribbs C. M., Koehler K. F., Sharkey N. A., Herald C. L., Kamano Y., Pettit G. R., Blumberg P. M. Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7197–7201. doi: 10.1073/pnas.85.19.7197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Wise B. C., Kuo J. F. Modes of inhibition by acylcarnitines, adriamycin and trifluoperazine of cardiac phospholipid-sensitive calcium-dependent protein kinase. Biochem Pharmacol. 1983 Apr 1;32(7):1259–1265. doi: 10.1016/0006-2952(83)90280-0. [DOI] [PubMed] [Google Scholar]
  139. Wolfman A., Macara I. G. Elevated levels of diacylglycerol and decreased phorbol ester sensitivity in ras-transformed fibroblasts. Nature. 1987 Jan 22;325(6102):359–361. doi: 10.1038/325359a0. [DOI] [PubMed] [Google Scholar]
  140. Yamanishi D. T., Graham M., Buckmeier J. A., Meyskens F. L., Jr The differential expression of protein kinase C genes in normal human neonatal melanocytes and metastatic melanomas. Carcinogenesis. 1991 Jan;12(1):105–109. doi: 10.1093/carcin/12.1.105. [DOI] [PubMed] [Google Scholar]
  141. Yoshizawa S., Fujiki H., Suguri H., Suganuma M., Nakayasu M., Matsushima R., Sugimura T. Tumor-promoting activity of staurosporine, a protein kinase inhibitor on mouse skin. Cancer Res. 1990 Aug 15;50(16):4974–4978. [PubMed] [Google Scholar]
  142. Young S., Parker P. J., Ullrich A., Stabel S. Down-regulation of protein kinase C is due to an increased rate of degradation. Biochem J. 1987 Jun 15;244(3):775–779. doi: 10.1042/bj2440775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  143. Zheng B., Oishi K., Shoji M., Eibl H., Berdel W. E., Hajdu J., Vogler W. R., Kuo J. F. Inhibition of protein kinase C, (sodium plus potassium)-activated adenosine triphosphatase, and sodium pump by synthetic phospholipid analogues. Cancer Res. 1990 May 15;50(10):3025–3031. [PubMed] [Google Scholar]
  144. de Vries D. J., Herald C. L., Pettit G. R., Blumberg P. M. Demonstration of sub-nanomolar affinity of bryostatin 1 for the phorbol ester receptor in rat brain. Biochem Pharmacol. 1988 Nov 1;37(21):4069–4073. doi: 10.1016/0006-2952(88)90097-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES